Expert Perspectives on a Treatment for Plaque Psoriasis

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Perspectives on a Treatment for Plaque Psoriasis



ReachMD Healthcare Image

What impact could a treatment for plaque psoriasis have on patients’ lives? Dive in to find out.

  • Sponsored by

  • Overview

    BIMZELX® is a development in psoriasis because it’s the first biologic that targets two important cytokines in psoriasis pathogenesis: IL-17A and IL-17F. So what other important information should we know about this therapy? Joining Dr. Andrew Blauvelt to speak about the latest updates are Dr. April Armstrong, Professor and Chief for the Division of Dermatology at UCLA Health and the David Geffen School of Medicine at UCLA, and Dr. Bruce Strober, Clinical Professor of Dermatology at Yale University School of Medicine.

    BIMZELX® is a registered trademark of the UCB Group of Companies.
    ©2024 UCB, Inc., 1950 Lake Park Drive, Smyrna, GA 30080. All rights reserved.
    2/2024 US-BK-2400214


    Suicidal Ideation and Behavior
    BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

    BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

    Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

    Liver Biochemical Abnormalities
    Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.  

    Inflammatory Bowel Disease
    Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs. 

    Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

    Most common adverse reactions (≥ 1%) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex Infections, acne, folliculitis, other Candida infections, and fatigue.

    For Full Prescribing Information, please visit:

Schedule25 Jun 2024